Predicting Risk of Plasmodium Vivax Microscopy-Detected Episodes Using Serological Markers in Patients With Plasmodium falciparum Malaria: A Multicountry Diagnostic Performance Evaluation
Authors:
- Maulina HafidzahMHMaulina Hafidzah
- Tamiru Shibiru DegagaTDTamiru Shibiru Degaga
- Michael ChristianMCMichael Christian
- Mohammad Shafiul AlamMAMohammad Shafiul Alam
- J Kevin BairdJBJ Kevin Baird
- Lauren SmithLSLauren Smith
- Dionne C ArgyropoulosDADionne C Argyropoulos
- Aisah R AmeliaAAAisah R Amelia
- Rintis NoviyantiRNRintis Noviyanti
Open Access
- 17 March 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (6) , e1470-e1479
Abstract
Plasmodium vivax presents a significant obstacle to malaria elimination due to its capacity to form dormant liver-stage hypnozoites that can cause relapses. Universal radical cure, which administers hypnozoite-targeting treatment to patients with P. falciparum malaria living in co-endemic areas, has potential to reduce P. vivax relapses. However, its implementation is hindered by the lack of a diagnostic tool for detecting hypnozoite-carriage. P. vivax serological exposure markers (SEMs) were evaluated as a screening tool in P. falciparum patients for predicting risk of P. vivax microscopy-detected episodes over the following 63 days. Analysis was performed using samples from participants in the PRIMA study from Ethiopia, Indonesia, and Bangladesh (NCT03916003). An existing random forest serological classification algorithm was used and evaluated for sensitivity and specificity, then further optimized by re-training a study-specific model. IgG antibodies were measured in 244 P. falciparum participant samples, of which 22 had a vivax microscopy-detected episode during follow-up. SEMs showed high sensitivity (82%) but low specificity (27%), likely due to sustained antibody responses in moderate-to-high transmission areas or undetected sub-microscopic P. vivax infections during follow-up. A study-specific algorithm increased specificity to 68%, but with a corresponding drop in sensitivity to 68%. Although P. vivax SEMs showed limited suitability for guiding radical cure in P. falciparum patients in this study (where the outcome was microscopy-detected vivax episodes), they could play a valuable role in building community trust and acceptance of universal radical cure when supported by strong communication and implementation strategies.Keywords
Funding Information
- Australian Academy of Science
- Bill and Melinda Gates Foundation
- National Health and Medical Research Council (#1173210)
- National Health and Medical Research Council (#2033264)
- National Health and Medical Research Council (#2016726)
- National Health and Medical Research Council (#2017630)
- National Health and Medical Research Council (#2024622)
- State Government of Victoria
- Sylvia and Charles Viertel Charitable Foundation
- Viertel Senior Medical Research
- Gates Family Foundation (INV-05142)
- Gates Family Foundation (INV-024368)
- Australian Centre of Research Excellence in Malaria Elimination
This publication has 25 references indexed in Scilit:
- Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trialThe Lancet, 2023
- Universal radical cure: prospects and challenges for malaria eliminationThe Lancet, 2023
- Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysisThe Lancet Infectious Diseases, 2023
- Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P. knowlesiCell Reports Medicine, 2022
- Plasmodium vivax – How hidden reservoirs hinder global malaria eliminationParasitology International, 2022
- Serology for Plasmodium vivax surveillance: A novel approach to accelerate towards eliminationParasitology International, 2022
- Development and validation of serological markers for detecting recent Plasmodium vivax infectionNature Medicine, 2020
- Plasmodium vivax in the Era of the Shrinking P. falciparum MapTrends in Parasitology, 2020
- Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2019
- Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasiteThe Lancet Infectious Diseases, 2009